Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 5.60% is 740% above its 5-year average of -0.87%, near the high end of its 5-year range (-1876.18%–22.27%).
101.47% above its 12-month average of -380.54%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1876.18%.
EBITDA MARGIN
5.60%
EBITDA MARGIN AVG TTM
-380.54%
EBITDA MARGIN AVG 3Y
0.10%
EBITDA MARGIN AVG 5Y
-0.87%
EBITDA MARGIN AVG 10Y
-2.52%
EBITDA MARGIN AVG 15Y
2.15%
EBITDA MARGIN AVG 20Y
6.84%
CURRENT VS TTM AVG
+101.47%
CURRENT VS 3Y AVG
+5641.24%
CURRENT VS 5Y AVG
+740.13%
CURRENT VS 10Y AVG
+322.44%
CURRENT VS 15Y AVG
+159.95%
CURRENT VS 20Y AVG
-18.17%
Cumberland Pharmaceuticals Inc.
Market Cap
$106.98M
EBITDA Margin
5.60%
TTM Avg
-380.54%
3Y Avg
0.10%
5Y Avg
-0.87%
Market Cap
$106.96M
EBITDA Margin
-4735.97%
TTM Avg
-4735.97%
3Y Avg
-4735.97%
5Y Avg
-4735.97%
Market Cap
$106.93M
EBITDA Margin
-893.25%
TTM Avg
-695.97%
3Y Avg
-642.31%
5Y Avg
-567.69%
Market Cap
$107.09M
EBITDA Margin
-6164.17%
TTM Avg
-4620.17%
3Y Avg
-2654.54%
5Y Avg
-2163.85%
Market Cap
$107.17M
EBITDA Margin
-10.96%
TTM Avg
-24.45%
3Y Avg
-32.87%
5Y Avg
-38.11%
Market Cap
$106.52M
EBITDA Margin
-624817.90%
TTM Avg
-624817.90%
3Y Avg
-624817.90%
5Y Avg
-624817.90%
Market Cap
$109.14M
EBITDA Margin
-699.90%
TTM Avg
-1930.94%
3Y Avg
-1689.05%
5Y Avg
-1903.35%
Market Cap
$104.68M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.26M
EBITDA Margin
6.31%
TTM Avg
-127.53%
3Y Avg
-89.97%
5Y Avg
-50.55%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cumberland Pharmaceuticals Inc. (CPIX) | $106.98M | 5.60% | -380.54% | 0.10% | -0.87% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | -4735.97% | -4735.97% | -4735.97% | -4735.97% |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | -893.25% | -695.97% | -642.31% | -567.69% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | -6164.17% | -4620.17% | -2654.54% | -2163.85% |
| Apyx Medical Corporation (APYX)vs › | $107.17M | -10.96% | -24.45% | -32.87% | -38.11% |
| Immunic, Inc. (IMUX)vs › | $106.52M | -624817.90% | -624817.90% | -624817.90% | -624817.90% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | -699.90% | -1930.94% | -1689.05% | -1903.35% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.26M | 6.31% | -127.53% | -89.97% | -50.55% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | N/A | N/A | N/A | N/A |
Gross Margin
83.4%
EBITDA Margin
5.6%
Operating Margin
-6.3%
Net Margin
-33.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1876.18% |
| 2026-03-31 | -20.29% |
| 2025-12-31 | -0.32% |
| 2025-09-30 | -11.18% |
| 2025-06-30 | 5.27% |
| 2025-03-31 | 22.27% |
| 2024-12-31 | -0.58% |
| 2024-09-30 | -3.23% |
| 2024-06-30 | 4.04% |
| 2024-03-31 | -5.10% |
| 2023-12-31 | -43.96% |
| 2023-09-30 | -3.77% |
| 2023-06-30 | 13.96% |
| 2023-03-31 | -1.13% |
| 2022-12-31 | -19.36% |
| 2022-09-30 | 11.00% |
| 2022-06-30 | -2.22% |
| 2022-03-31 | 3.24% |
| 2021-12-31 | -39.39% |
| 2021-09-30 | -6.07% |
| 2021-06-30 | -2.29% |
| 2021-03-31 | 8.57% |
| 2020-12-31 | -5.09% |
| 2020-09-30 | -0.20% |
| 2020-06-30 | -4.15% |
| 2020-03-31 | -8.33% |
| 2019-12-31 | 0.93% |
| 2019-09-30 | -7.84% |
| 2019-06-30 | 4.29% |
| 2019-03-31 | 7.56% |
| 2018-12-31 | -10.67% |
| 2018-09-30 | -12.88% |
| 2018-06-30 | -1.65% |
| 2018-03-31 | -20.49% |
| 2017-12-31 | -2.39% |
| 2017-09-30 | -1.60% |
| 2017-06-30 | -11.86% |
| 2017-03-31 | 0.04% |
| 2016-12-31 | -4.36% |
| 2016-09-30 | 8.46% |
| 2016-06-30 | 6.53% |
| 2016-03-31 | 1.05% |
| 2015-12-31 | 4.41% |
| 2015-09-30 | 10.22% |
| 2015-06-30 | 14.09% |
| 2015-03-31 | 6.51% |
| 2014-12-31 | 15.64% |
| 2014-09-30 | 16.16% |
| 2014-06-30 | 16.62% |
| 2014-03-31 | 9.92% |
| 2013-12-31 | -26.80% |
| 2013-09-30 | -18.50% |
| 2013-06-30 | -11.59% |
| 2013-03-31 | 15.76% |
| 2012-12-31 | 24.64% |
| 2012-09-30 | 25.55% |
| 2012-06-30 | 16.61% |
| 2012-03-31 | 8.42% |
| 2011-12-31 | 14.96% |
| 2011-09-30 | 25.05% |
| 2011-06-30 | 27.08% |
| 2011-03-31 | 15.66% |
| 2010-12-31 | 19.45% |
| 2010-09-30 | 21.46% |
| 2010-06-30 | 11.57% |
| 2010-03-31 | 10.28% |
| 2009-12-31 | 8.44% |
| 2009-09-30 | 18.97% |
| 2009-06-30 | 7.80% |
| 2009-03-31 | 24.60% |
| 2008-12-31 | 17.04% |
| 2008-09-30 | 26.99% |
| 2008-06-30 | 24.05% |
| 2008-03-31 | 23.67% |
| 2007-12-31 | 20.50% |
| 2007-09-30 | 31.22% |
| 2007-06-30 | 30.25% |
| 2007-03-31 | 24.36% |
| 2006-12-31 | 18.85% |
| 2006-09-30 | 32.70% |
| 2006-06-30 | 21.03% |
| 2006-03-31 | -85.27% |
